KLRG1 and type 1 diabetes mellitus: We previously reported that co-expression of TIGIT and KLRG1 marked CD8+ T cells that had phenotypic and functional features of exhaustion, including an EOMES signature, and that these cells expanded following teplizumab (anti-CD3) therapy in individuals with T1D (12–14).